Background: Patients (pts) with advanced cancer have high rates of healthcare resource utilization at the end of life (EOL). Immunotherapy (IO) has changed the treatment landscape for many patients with cancer. The impact of IO on resource utilization at the EOL for pts with metastatic disease, including emergency department (ED) visits, hospitalizations, and referrals to hospice is unknown. Methods: We conducted a single center, retrospective analysis of pts treated with PD-1/ L1 or CTLA-4 antibodies alone or in combination from 2011 -2017. We identified 1,113 pts from electronic health records and present here clinical information for 306 pts with metastatic disease and end of life outcome data for 188 decedents. Survival curves were compared using log-rank test for pts by disease, treatment type, ECOG performance status (PS) at treatment start, and age. Hospice referral rate was compared using Fisher's exact test. Results: Of the 306 pts, 131 (43%) had melanoma, 42 (14%) had renal cell carcinoma, 33 (11%) had non-small cell lung cancer, 22 (7%) had head and neck carcinoma, and 78 (25%) had another advanced malignancy. Treatment consisted of nivolumab in 130 (42%) pts, ipilimumab in 73 (24%), pembrolizumab in 59 (19%), nivolumab/ipilimumab in 23 (8%), atezolizumab in 9 (3%), and other IO combinations in 12 (4%). Of the 188 (61%) pts who died, 93 (49%) had at least one ED visit in the last month of life, 110 (59%) had at least one hospitalization, and 21 (11%) died in the hospital. Of all pts who died, 156 (83%) had hospice referral with a median of 11 days (range 1-420) between hospice referral and death. Overall survival (OS) was not associated with disease type (p ¼ 0.11) or treatment (p ¼ 0.832), but was associated with ECOG PS (p ¼ 0.013). Referral to hospice did not vary by disease type (p ¼ 0.945), treatment type, (p ¼ 0.809) or age (p ¼ 0.432), but did vary by ECOG PS (p ¼ 0.006). Death within 72 hours of hospice referral rate varied significantly by inpatient or outpatient referral (p ¼ 0.002). Conclusions: Hospitalizations and ED visits are frequent at the EOL among pts who received IO for advanced malignancies. There was a high referral rate to hospice, but the median time between hospice referral and death was short. Interventions to decrease aggressive EOL care are needed. Legal entity responsible for the study: Jarred Burkart. Background: The recommendation to use palliative chemotherapy (PC) in patients (pts) with advanced cancer and poor performance status (ECOG-PS) is controversial and could be harmful. However, in routine practice some oncologists still recommend it. We sought to identify the outcomes and related prognostic factors of PC in these pts treated in a large academic cancer center. Methods: We retrospectively reviewed all consecutive pts with poor ECOG-PS metastatic solid tumors who received PC during hospitalization for symptom control from January 2015 to September 2017. Eligible pts had ECOG-PS 3/4 and started first line PC or had ECOG-PS 2 and started second or further lines. Pts with known chemo-sensible tumors (germ cell, ovary, small cell lung cancer) and primary central nervous system were excluded. The primary end point was survival rate within 30 days from the date of first cycle. Logistic regression was used to identify prognostic factors associated with this mortality rate. Results: We identified 228 consecutive pts. The median age was 56 years old, 133 pts (58%) were female, 150 pts (66%) were chemotherapy-naïve and almost half of pts had primary gastrointestinal tumors. 21.9%, 66.7% and 11.4% pts had ECOG-PS 2, 3 and 4, respectively. With a median follow-up of 49 days, 224 pts (98.2%) died. Nearly two thirds (N ¼ 142) of pts died while hospitalized, with 31 (13.8%) dying while in ICU, 27 pts (12%) died in a hospice and 2 pts passed away at home. The median overall survival was 38.5 days and the survival rates within 30 and 60 days of chemotherapy were 55.7% and 38.5%, respectively. In the multivariate analysis, ECOG-PS 3/4 (OR 2.45; p ¼ 0.015) and baseline values of anemia (OR 0.41; p ¼ 0.034), hypercalcemia (OR 2.71; p ¼ 0.410) and elevated total bilirubin level (5.14; p < 0.001) were significantly associated with 30-day mortality.
Background: The recommendation to use palliative chemotherapy (PC) in patients (pts) with advanced cancer and poor performance status (ECOG-PS) is controversial and could be harmful. However, in routine practice some oncologists still recommend it. We sought to identify the outcomes and related prognostic factors of PC in these pts treated in a large academic cancer center. Background: Integration of oncology and palliative care (PC) combines two paradigms: the tumour-directed approach, which is the main focus of oncology, and the host-directed approach, which is the focus of PC. Contemporary PC aims to prevent, treat and reduce symptoms and suffering and to preserve and improve quality of life. A Lancet Oncology Commission was written on how PC and oncology can be integrated by combining these two approaches focusing content, models, organization of cancer care, public health, politics, education and research. Methods: An international panel was established, consisting of experts in oncology, PC, public health and psycho-oncology. Literature searches were conducted, author meetings were held, and an interactive writing process was conducted. Results: Integration is a complex process that involves various components of the health care system. The published RCTs on integration demonstrate health gains, but how and when to integrate is uncertain. Still, early delivery of specialist palliative care promotes patient-centeredness including shared-decision making, family involvement and regular use of patient-reported outcome measures. Barriers to integration include the perception of PC as end-of-life care, deficient planning at local, national and international levels, and insufficient infrastructure and funding. Furthermore, death and dying are stigmatized. The present competence in combined oncology and PC varies substantially and must be defined at all levels. The commission proposes to use standardized care pathways (SCPs) and multidisciplinary teams (MDTs) to promote integration. Integration raises new research questions: how much, when and how should PC be delivered and what is the minimum model for good care? Conclusions: Integration involves the transition from a dualistic perspective -the tumor and the host-to a combined perspective. Integration must be recommended by health care authorities and decision-takers, followed by resource allocation and priority-setting. In all areas, the present volume of PC is too small to support integration on a broad scale. Implementation of integrated models is best secured by MDTs and SCPs. The combined perspective must be reflected in care models, education and research funding. Legal entity responsible for the study: Oslo University Hospital. 
